Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.46) by 17.39 percent. This is a 216.67 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $2.02 million which missed the analyst consensus estimate of $3.10 million by 34.71 percent. This is a 91.45 percent decrease over sales of $23.66 million the same period last year.